ClinicalTrials.gg
Enrolling by invitationNCT06075901Updated Sep 16, 2026

Reliability and Performance Analysis of the Use of Tissue Flossing for Blood Flow Restriction.

An interventional study of Tissue Flossing and Blood Flow Restriction Cuff in Hypertrophy and Muscle Strength, sponsored by Paulista University. Enrolling by invitation at 1 site in Brazil. Open to participants aged 18 Years to 30 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-16.

Sponsored by Paulista University · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
136
Allocation
Randomized
Ages
18 Years to 30 Years
Sex
All
01

Study summary

Blood flow restriction (RFS) is a widely studied technique that combines low-intensity exercise with vascular occlusion, resulting in muscular benefits. However, its application is challenging due to methodological variations and equipment costs. Tissue Flossing (TF) appears as an affordable alternative, but lacks solid scientific evidence.

Read the detailed description

Objectives: to evaluate the intra- and inter-rater reliability of the occlusion pressure generated by TF, investigate the reproducibility of TF application on different days and compare TF with traditional RFS in terms of muscle gains.

Methods: the study is divided into two stages: First stage, randomized controlled crossover clinical trial, 80 healthy individuals aged 18 to 30 years old evaluated to determine the reliability of the TF. Participants will follow one of two types of randomization, with exclusions based on health criteria. Assessments include anthropometric characteristics, determination of occlusion pressure (POT), identification of 40% and 80% of POT, flow data and arterial diameter after TF application. Statistical analysis will use the intraclass correlation index (ICC) and specific models for intra- and inter-rater analyses. Second stage, randomized controlled clinical trial with parallel groups, 110 recreational athletes will be evaluated over four weeks. The initial procedures involve anthropometric assessments, POT determination, myotonometry, ultrasound, perceptual scale and 1RM test, applied to both lower limbs. Participants will perform a lower limb training protocol, using RFS and TF on different legs, following myotonometric and perceptual assessments. After training, final assessments will measure the same parameters initially assessed. Statistical analysis will use normality tests, Generalized Mixed Models and effect size analysis in SPSS software, with a significance level of p\<0.05. Expected results: This study is expected to provide information on the reliability and reproducibility of TF in generating occlusion pressure. Furthermore, we seek to validate TF by comparing it with traditional RFS in terms of muscle gains. If effective, TF could become an affordable option to promote muscle gains, in different application scenarios.

Participants will be duly informed about the procedures and objectives of this study, and after agreeing, they will sign an informed consent form, effectively becoming part of it. In the consent form, participants will be asked if they agree to the use of their data if they choose to withdraw from the study. Participants will also be asked for permission for the research team to share relevant data with people at universities participating in the research or regulatory authorities, where relevant. The study will be sent for consideration and approval to the Research Ethics Committee of FCT/UNESP, Presidente Prudente, SP, Brazil.

02

Conditions studied

  • Hypertrophy
  • Muscle Strength

Browse trials for

Keywords

  • tissue flossing
  • blood flow restriction
03

In context

Hypertrophy

139 studies on the registry are indexed under Hypertrophy; 22 are open to participants now.

This study's planned enrollment of 136 is above the median of 34 across 112 interventional studies indexed under Hypertrophy.

Browse Hypertrophy studies →

Lead sponsor

Paulista University is the lead sponsor of 23 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 30 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals who present one or more of the following characteristics will not be included:
  • 1 presence of any health condition that contraindicates or prevents exercise;
  • 2 diabetes and diagnosed high blood pressure;
  • 3 inflammatory, psychiatric, cardiovascular and/or respiratory rheumatological disease; - -4 being dependent on alcohol, consuming drugs and/or being a smoker;
  • 5 history of knee surgery (e.g., meniscal repair and ligament reconstruction) or recent lower limb musculoskeletal injury that may impair performance during tests or interventions (e.g., muscle injury, tendinopathy, patellofemoral pain and/or back pain column in the last six months);
  • 6 use of ergogenic supplements to improve physical performance and/or muscle mass and/or vasoactive medications;
  • 7 having one or more risk factors predisposing to thromboembolism

Exclusion criteria

Exclusion Criteria:

  • Participants will be excluded from the study if they:
  • 1 have a health problem that does not allow them to continue;
  • 2 wish to leave the study;
  • 3 not sign the consent form
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
136 participants (estimated)

Study arms

  • Active comparator
    Blood Flow Restriction with Cuffing

    The participant will use the Cuffing for Blood Flow Restriction training

    Device: Blood Flow Restriction Cuff · Other: Training Protocol

  • Experimental
    Blood Flow Restriction with Tissue Flossing

    The participant will use Tissue Flossing for Blood Flow Restriction training

    Device: Tissue Flossing · Other: Training Protocol

Interventions

  • DeviceTissue Flossing

    Tissue Flossing ia a elastic band that when applied exerts an external pressure above or below a muscle or joint of the extremities.

  • DeviceBlood Flow Restriction Cuff

    Inflatable device that exerts an external pressure above a muscle or joint of the extremities.

  • OtherTraining Protocol

    The lower limb resistance training protocol will follow that recommended in the study by Patterson et al. for resistance training, and will last 4 weeks, with 3 training sessions per week, with a day break between sessions.

06

What researchers measure

Primary outcomes

  1. Occlusion pressures (AOP, 80% and 40% of AOP)

    To determine the AOP, the Doppler equipment transducer will be used, which will be positioned over the posterior tibial artery to capture the auscultatory pulse. A blood pressure cuff will be fixed to the participant's thigh close to the region of the inguinal fold of the dominant limb, and then with the inflatable region of the cuff on the medial portion of the thigh covering the femoral artery, it will be progressively inflated, waiting 15 seconds every 30 mmHg until the point at which the auscultatory pulse of the tibial artery is interrupted.

    Time frame: First and Secund Stage - [Time Frame: baseline]

  2. Assessment of arterial flow and diameter

    A Sonoline Sienna® vascular ultrasound will be used combined with a 40mm B-mode ultrasonic transducer with a 7.5 MHz linear beam, which will be coated with gel for acoustic contact and positioned longitudinally to the posterior tibial artery, enabling variables to be assessed. Doppler flow measurements of MI (peak systolic velocity \[cm/s\], end-diastolic velocity \[cm/s\] and arterial diameter).

    Time frame: First Stage - [Time Frame: baseline and all subsequent assessments]

  3. Perceptual parameter

    The perceptual parameter will be evaluated using a Borg CR10+ scale, representing the perception of discomfort, 0 represents no discomfort and 10 extremely uncomfortable.

    Time frame: First and Secund Stage - [Time Frame: baseline and all subsequent assessments]

  4. Tissue Flossing Assessment

    The application of tissue flossing on the leg will be carried out by always passing the elastic tape with 50% of the tape over the next strip, until the end of the elastic tape.

    Time frame: First Stage - [Time Frame: The subsequent assessments]

  5. Weight

    It will be collected with a weight balance

    Time frame: First and Secund Stage- [Time Frame: Baseline ]

  6. Height

    It will be collected with a stadiometer

    Time frame: First and Secund Stage- [Time Frame: Baseline ]

  7. Body Fat

    It will be collected with a adipometer

    Time frame: First and Secund Stage- [Time Frame: Baseline ]

  8. Arterial pressure

    It will be collected with a sphygmomanometer

    Time frame: First and Secund Stage- [Time Frame: Baseline ]

  9. Perimetry of the dominant lower limb

    It will be defined by the Waterloo Footedness

    Time frame: First and Secund Stage- [Time Frame: Baseline ]

  10. Limb length

    Identified with a measuring tape

    Time frame: First and Secund Stage- [Time Frame: Baseline ]

  11. Perceived exertion scale

    Adapted BORG scale, with 0 being "no effort" and 10 "maximum effort".

    Time frame: Secund Stage- [Time Frame: at the end of the training sessions]

  12. Method preference

    Participants must answer a brief questionnaire about their preference for one of the RFS methods carried out, and justify why they chose it.

    Time frame: Secund Stage- [Time Frame: final evaluation]

  13. 1 Maximum Repetition Test

    The participant must be positioned seated on the extension chair with knees and feet hip-width apart, knees at 90° flexion determined by goniometry, hands holding the handles adjacent to the hips and lumbosacral spine in a firm position in contact with the back of the chair. 1 repetition should be performed to familiarize the movement and 10 repetitions to warm up. At the beginning of the test, they will be instructed to maintain a movement pattern and avoid compensation. The RM is then defined by the highest load at which the participant is capable of performing 1 repetition without compensation.

    Time frame: Secund Stage- [Time Frame: baseline and final evaluation]

  14. Myotonometry

    Myotonometry will be assessed using the MyotonPRO® tool, which consists of a portable, wireless and non-invasive device. The measurement will be carried out once, and in each shot, the following myotonometry parameters will be calculated: the state of tension (tone) and biomechanical properties (rigidity and elasticity).

    Time frame: Secund Stage- [Time Frame: baseline during follow-up and final evaluation]

  15. Ultrasound

    The assessment of the muscular structure will be carried out using ultrasound images of the participant's lower limbs, which will be captured using BodyMetrix BX-2000. Participants will be assessed in the supine position with legs fully extended and muscles relaxed. The ultrasound transducer will be covered with water-soluble transmission gel and positioned perpendicular to the skin over the muscle.

    Time frame: Secund Stage- [Time Frame: baseline and final evaluation]

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2025 to primary completion in May 2026, 9 months.

Of 65 non-industry interventional studies with no phase under Hypertrophy, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 22. This study's 9 months is below that.

Counting every sponsor, half of 78 studies reached it within 13 months; a quarter within 6 and three quarters within 22.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2023
First posted
Oct 10, 2023
StartActual
Aug 1, 2025
Primary completionActual
May 2, 2026
CompletionEst.
Jul 2027
Last update
Sep 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06075901
Lead sponsor
Paulista University
Responsible party
Franciele Marques Vanderle (Principal investigator, Paulista University) — Principal investigator
First posted
Oct 10, 2023
Start date
Aug 1, 2025
Primary completion
May 2, 2026
Completion
Jul 2027 (estimated)
Last update
Sep 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion